Bristol-based bio-pharmaceutical consultancy eXmoor Pharma, which specialises in world-leading cell and gene therapy, has appointed Dr Lucy Foley as chief technology officer.
Lucy, pictured, brings with her more than 10 years’ industry experience focused on technology, process development and delivering large, complex projects. 
She joins eXmoor after eight years at the Centre for Process Innovation (CPI), with her most recent position as director of biologics and Covid response.
Lucy is already a familiar face to the eXmoor team as she is as a founding leadership team member of the amc (ATMP Manufacturing Community) board, along with eXmoor CEO Dr Angela Osborne.
She also collaborated with eXmoor in 2013 when she was lead biopharmaceutical engineer at CPI on the concept design of the organisation’s Darlington-based National Biologics Manufacturing Centre.
She recently led the establishment of the UK’s RNA Centre of excellence in response to the Covid-19 pandemic as a member of the UK Vaccines Taskforce.
This established both PD and GMP facilities in the UK to provide resilience against future variants and pandemics by onshoring manufacturing and expertise.
Prior to joining CPI, she was an academic at Newcastle University in its Business School and Chemical Engineering Department, where she worked with on the adoption and process industrialisation of advanced therapies.
Lucy said: “I’m thrilled to have joined eXmoor and to have the opportunity to work alongside Angela and the board.
“I am excited to be part of its growth journey and its significant contribution to growing the UK as a world leader in cell and gene therapies.
Angela added: “I welcome Lucy to our growing team here at eXmoor. Her unprecedented industry experience will be integral to the next phase of our growth.”
Lucy holds a Master’s degree in biochemical engineering with bioprocess management from University College London, and an engineering doctorate in biochemical engineering and bioprocess leadership from University College London. 
Founded in 2004, eXmoor has grown into a globally recognised leader in its field and has completed more than 400 projects across 15 countries.
Its globally recognised team of scientists, consultants and engineers, based at the Future Space science hub on UWE’s Frenchay campus, pictured, develop cell and gene therapy (CGT) biomanufacturing projects and support businesses in commercialising research processes and developing fully licensed facilities.
It recently signed a deal to support New Zealand’s blood service as it builds and establishes a new site near Auckland.
The deal came on the back of work undertaken by eXmoor in the UK for NHS Blood &Transplant (NHSBT).
